Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

EU Grants EUR 6m to Athera´s Cardiovascular Disease Antibody Therapy

Published: Monday, June 17, 2013
Last Updated: Monday, June 17, 2013
Bookmark and Share
EUR 6m grant has been provided to the CARDIMMUN consortium.

Athera Biotechnologies AB has announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union’s Seventh Framework Programme for Research (FP7) through a collaborative research grant.

Karolinska Development AB owns 65% of Athera Biotechnologies AB.

Athera’s fully human monoclonal antibody PC-mAb is targeting phosphorylcholine and is being developed for the treatment of patients with an increased risk of atherosclerosis related cardiovascular events and death.

This includes myocardial infarction patients and patients with peripheral arterial disease undergoing vein graft surgery.

“The grant underpins the level of innovation of the PC-mAb project and will substantially contribute to the pace of the future development”, comments Torbjörn Bjerke, CEO of Karolinska Development.

The EUR 6m grant has been provided to the CARDIMMUN consortium, consisting of Athera, Leiden University Medical Center (LUMC), Turku PET Center (Turku University), Clinical Trial Consultants (CTC) and Smerud Medical Research.

The project has a total budget of nearly EUR 8m and will be running over three years, focusing on key preclinical activities and clinical trials aimed at demonstrating proof-of-concept of this new cardiovascular treatment.

LUMC is the project coordinator and will be leading the project together with Athera.

“I am very pleased that Athera is part of the CARDIMMUN consortium and thereby receives support from the FP7. With this non-dilutive funding, Athera will be able to take its proprietary monoclonal antibody PC-mAb through major milestones”, says Carina Schmidt, CEO of Athera Biotechnologies.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Karolinska Development Appoints New Chief Financial Officer
Christian Tange will start working with Karolinska Development from February 1, 2014.
Thursday, January 30, 2014
NovaSAID Initiates Partnership with Cadila Pharmaceuticals
Strategic partnership to develop innovative treatments in inflammation and pain management.
Friday, January 10, 2014
EU Research Grants Awarded to Three of Karolinska Development’s Portfolio Companies
Goal is to develop new ways to treat infectious diseases.
Monday, December 30, 2013
Karolinska Development Invests in Forendo Pharma
The stepwise funding commitments are expected to reach EUR 10m over a period of three years, of which Karolinska Development will invest up to EUR 3.0m.
Wednesday, June 26, 2013
Athera and Boehringer Ingelheim Enter Into an Option Agreement
Agreement on a novel therapy for atherosclerosis.
Friday, June 21, 2013
Dilaforette - Phase II Study with Sevuparin for the Treatment of Severe Malaria Initiated
Company gets approval from the regulatory authority to start Phase II trial in India.
Thursday, May 16, 2013
Preliminary Results of a Phase II Study Indicates that Axelar’s AXL1717 is Effective in treating NSCLC Patients
Axelar to finalize the trial with approximately 100 patients.
Monday, April 08, 2013
Pergamum AB Announces a Strategic Collaboration with Cadila Pharmaceuticals
Both Companies will collaborate on the preclinical and clinical development of a novel therapeutic peptide.
Monday, February 11, 2013
Aprea Announces Positive Data from a Clinical Phase I/II Study with APR-246
Results from the study have been published in the Journal of Clinical Oncology.
Wednesday, September 19, 2012
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!